Research efforts have extensively explored the identification of biomarkers overexpressed in tumor cells, including cell adhesion molecules, CD44, folate receptors (FR), transferrin (Tf), glucose transporter protein type 1 (GLUT1), LAT1, and biotin receptors, to refine the targeting strategies for cancer therapeutic delivery. The gene discussed is SLC2A1; the disease is neoplasm.